. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review . Expert Rev Respir Med 2015 ; 9 : 533 – 549 . 59. Christoph DC Eberhardt WE . Systemic treatment of malignant pleural mesothelioma
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory and Miranda Hughes
Margaret A. Tempero, Mokenge P. Malafa, Stephen W. Behrman, Al B. Benson III, Ephraim S. Casper, E. Gabriela Chiorean, Vincent Chung, Steven J. Cohen, Brian Czito, Anitra Engebretson, Mary Feng, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Andrew M. Lowy, Wen Wee Ma, Nipun B. Merchant, Sean J. Mulvihill, Peter Muscarella II, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Sushanth Reddy, Aaron R. Sasson, Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns and Deborah A. Freedman-Cass
following systemic treatment of initially locally unresectable disease . Ann Surg Oncol 2012 ; 19 : 1663 – 1669 . 45. Faris JE Blaszkowsky LS McDermott S . FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital
Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy and Janine Giese-Davis
Trialists' Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women . Lancet 1992 ; 339 : 1 – 15 . 25
Neil K. Taunk, Daniel E. Spratt, Mark Bilsky and Yoshiya Yamada
prognosis in patients with RCC. 3 , 4 Even with these advances in systemic treatment, radiation therapy (RT) continues to play a significant role in managing patients with metastatic disease to the brain and spine. RT is used for palliation of painful bone
Zeynep Eroglu, Odicie Fielder and George Somlo
breast cancer patients receiving first-line systemic treatment . Breast Cancer Res 2011 ; 13 : R67 . 36. Munzone E Botteri E Sandri MT . Prognostic value of circulating tumor cells according to immunohistochemically defined molecular
Paolo Marchetti, Raymond Voltz, Carmen Rubio, Didier Mayeur and Andreas Kopf
have no curative treatment options, and that it should be integrated soon after completing cancer staging and starting disease-specific systemic treatment and delivered at the same location as anticancer therapy. Examples of timing for integration of
Rupali Roy and Leo I. Gordon
developed by the international follicular lymphoma prognostic factor project . J Clin Oncol 2009 ; 27 : 4555 – 4562 . 11 Ardeshna KM Smith P Norton A . Long-term effect of a watch and wait policy versus immediate systemic treatment for
Manish A. Shah and David P. Kelsen
; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research . J Clin Oncol 2007 ; 25 : 3217 – 3223 . 57. Van Cutsem E
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory and Deborah A. Freedman-Cass
unresectable, advanced, or metastatic CRC (mCRC) were managed with a continuum of care that included 20 first-line systemic treatment options, 33 second-line options, and 13 options for subsequent therapies in up to 7 lines of treatment. 28 , 29 A growing list
Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee and Joseph E. Ippolito
, distant metastatic disease, and a combination of both is critical, because this will affect whether the patient will receive local salvage and or systemic treatment. 52 Therefore, imaging modalities that have the ability to detect recurrent local and
